SYNI Projected Dividend Yield

Synvista Therapeutics, Inc. ( OTCBB : SYNI )

Alteon is a product-based biopharmaceutical company engaged primarily in the development of small molecule drugs to treat and prevent cardiovascular disease and diabetes. As of Dec 31 2006, Co.'s lead drug candidate, alagebrium chloride or alagebrium (formerly ALT-711), was a glycation end-product (A.G.E.) crosslink breaker being developed for diastolic heart failure (DHF). In addition, Co. has expanded its portfolio with another compound in Phase II clinical development for cardiovascular complications of diabetes through its Jul 2006 acquisition of HaptoGuard, Inc.

21 YEAR PERFORMANCE RESULTS